Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis

Mónica Kurte, Javiera Bravo-Alegría, Alexander Torres, Vania Carrasco, Cristina Ibáñez, Ana María Vega-Letter, Catalina Fernández-O'Ryan, Carlos E. Irarrázabal, Fernando E. Figueroa, Rodrigo A. Fuentealba, Claudia Riedel, Flavio Carrión

Resultado de la investigación: Article

18 Citas (Scopus)

Resumen

Potent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classical and atypical scores of EAE, associated with Th1 and Th17 response, respectively, and also Treg lymphocytes, were evaluated. MSCs administration at the onset (EAE+MSConset) induced an important amelioration of the clinical signs and less lasting effect at the peak of EAE (EAE+MSCpeak). No effect was observed when MSCs were applied after EAE stabilization (EAE+MSClate). Surprisingly, EAE atypical signs were detected in EAE+MSCpeak and EAE+MSClate mice. However, no correlation was found in Th17/Th1 ratio. Interestingly, regardless of time administration, MSCs significantly reduced IL-6 and also T-bet, RORγT, and Foxp3 mRNA levels in brain samples of EAE mice. The downregulation of IL-6 could restore the well-functioning of the blood-brain barrier of EAE mice, correlated with a decreased number of brain infiltrating leukocytes. These results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of MSCs for multiple sclerosis.

Idioma originalEnglish
Número de artículo140170
PublicaciónStem Cells International
Volumen2015
DOI
EstadoPublished - 2015

Huella dactilar

Autoimmune Experimental Encephalomyelitis
Mesenchymal Stromal Cells
Intravenous Administration
Bone Marrow
Interleukin-6
Brain
Therapeutic Uses
Immunosuppressive Agents
Blood-Brain Barrier
Research
Autoimmune Diseases
Multiple Sclerosis
Leukocytes
Down-Regulation

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Citar esto

Kurte, Mónica ; Bravo-Alegría, Javiera ; Torres, Alexander ; Carrasco, Vania ; Ibáñez, Cristina ; Vega-Letter, Ana María ; Fernández-O'Ryan, Catalina ; Irarrázabal, Carlos E. ; Figueroa, Fernando E. ; Fuentealba, Rodrigo A. ; Riedel, Claudia ; Carrión, Flavio. / Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis. En: Stem Cells International. 2015 ; Vol. 2015.
@article{c83edbab798a4f999d46dc30176ebfe5,
title = "Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis",
abstract = "Potent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classical and atypical scores of EAE, associated with Th1 and Th17 response, respectively, and also Treg lymphocytes, were evaluated. MSCs administration at the onset (EAE+MSConset) induced an important amelioration of the clinical signs and less lasting effect at the peak of EAE (EAE+MSCpeak). No effect was observed when MSCs were applied after EAE stabilization (EAE+MSClate). Surprisingly, EAE atypical signs were detected in EAE+MSCpeak and EAE+MSClate mice. However, no correlation was found in Th17/Th1 ratio. Interestingly, regardless of time administration, MSCs significantly reduced IL-6 and also T-bet, RORγT, and Foxp3 mRNA levels in brain samples of EAE mice. The downregulation of IL-6 could restore the well-functioning of the blood-brain barrier of EAE mice, correlated with a decreased number of brain infiltrating leukocytes. These results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of MSCs for multiple sclerosis.",
author = "M{\'o}nica Kurte and Javiera Bravo-Alegr{\'i}a and Alexander Torres and Vania Carrasco and Cristina Ib{\'a}{\~n}ez and Vega-Letter, {Ana Mar{\'i}a} and Catalina Fern{\'a}ndez-O'Ryan and Irarr{\'a}zabal, {Carlos E.} and Figueroa, {Fernando E.} and Fuentealba, {Rodrigo A.} and Claudia Riedel and Flavio Carri{\'o}n",
year = "2015",
doi = "10.1155/2015/140170",
language = "English",
volume = "2015",
journal = "Stem Cells International",
issn = "1687-9678",
publisher = "Hindawi Publishing Corporation",

}

Kurte, M, Bravo-Alegría, J, Torres, A, Carrasco, V, Ibáñez, C, Vega-Letter, AM, Fernández-O'Ryan, C, Irarrázabal, CE, Figueroa, FE, Fuentealba, RA, Riedel, C & Carrión, F 2015, 'Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis', Stem Cells International, vol. 2015, 140170. https://doi.org/10.1155/2015/140170

Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis. / Kurte, Mónica; Bravo-Alegría, Javiera; Torres, Alexander; Carrasco, Vania; Ibáñez, Cristina; Vega-Letter, Ana María; Fernández-O'Ryan, Catalina; Irarrázabal, Carlos E.; Figueroa, Fernando E.; Fuentealba, Rodrigo A.; Riedel, Claudia; Carrión, Flavio.

En: Stem Cells International, Vol. 2015, 140170, 2015.

Resultado de la investigación: Article

TY - JOUR

T1 - Intravenous administration of bone marrow-derived mesenchymal stem cells induces a switch from classical to atypical symptoms in experimental autoimmune encephalomyelitis

AU - Kurte, Mónica

AU - Bravo-Alegría, Javiera

AU - Torres, Alexander

AU - Carrasco, Vania

AU - Ibáñez, Cristina

AU - Vega-Letter, Ana María

AU - Fernández-O'Ryan, Catalina

AU - Irarrázabal, Carlos E.

AU - Figueroa, Fernando E.

AU - Fuentealba, Rodrigo A.

AU - Riedel, Claudia

AU - Carrión, Flavio

PY - 2015

Y1 - 2015

N2 - Potent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classical and atypical scores of EAE, associated with Th1 and Th17 response, respectively, and also Treg lymphocytes, were evaluated. MSCs administration at the onset (EAE+MSConset) induced an important amelioration of the clinical signs and less lasting effect at the peak of EAE (EAE+MSCpeak). No effect was observed when MSCs were applied after EAE stabilization (EAE+MSClate). Surprisingly, EAE atypical signs were detected in EAE+MSCpeak and EAE+MSClate mice. However, no correlation was found in Th17/Th1 ratio. Interestingly, regardless of time administration, MSCs significantly reduced IL-6 and also T-bet, RORγT, and Foxp3 mRNA levels in brain samples of EAE mice. The downregulation of IL-6 could restore the well-functioning of the blood-brain barrier of EAE mice, correlated with a decreased number of brain infiltrating leukocytes. These results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of MSCs for multiple sclerosis.

AB - Potent immunosuppressive and regenerative properties of mesenchymal stem cells (MSCs) position them as a novel therapy for autoimmune diseases. This research examines the therapeutic effect of MSCs administration at different disease stages in experimental autoimmune encephalomyelitis (EAE). Classical and atypical scores of EAE, associated with Th1 and Th17 response, respectively, and also Treg lymphocytes, were evaluated. MSCs administration at the onset (EAE+MSConset) induced an important amelioration of the clinical signs and less lasting effect at the peak of EAE (EAE+MSCpeak). No effect was observed when MSCs were applied after EAE stabilization (EAE+MSClate). Surprisingly, EAE atypical signs were detected in EAE+MSCpeak and EAE+MSClate mice. However, no correlation was found in Th17/Th1 ratio. Interestingly, regardless of time administration, MSCs significantly reduced IL-6 and also T-bet, RORγT, and Foxp3 mRNA levels in brain samples of EAE mice. The downregulation of IL-6 could restore the well-functioning of the blood-brain barrier of EAE mice, correlated with a decreased number of brain infiltrating leukocytes. These results suggest that the inflammatory status is important to be considered for administering MSCs in autoimmune pathologies, leading to a further research to clarify the effect of MSCs for multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=84925637621&partnerID=8YFLogxK

U2 - 10.1155/2015/140170

DO - 10.1155/2015/140170

M3 - Article

AN - SCOPUS:84925637621

VL - 2015

JO - Stem Cells International

JF - Stem Cells International

SN - 1687-9678

M1 - 140170

ER -